Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan.
Department of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences 1, Tokyo, Japan.
J Antibiot (Tokyo). 2018 Feb;71(2):298-317. doi: 10.1038/ja.2017.114. Epub 2017 Nov 1.
In order to modify lincomycin at the C-6 and C-7 positions, we prepared target molecules, which have substituted pipecolinic acid at the 6-amino group and a para-substituted phenylthio group at the C-7 position, in application of palladium-catalyzed cross-coupling as a key reaction. As the result of structure-activity relationship (SAR) studies at the 6-position, analogs possessing 4'-cis-(cyclopropylmethyl)piperidine showed significantly strong antibacterial activities against Streptococcus pneumoniae and Streptococcus pyogenes with an erm gene. On the basis of SAR, we further synthesized novel analogs possessing 4'-cis-(cyclopropylmethyl)piperidine by transformation of a C-7 substituent. Consequently, novel derivatives possessing a para-heteroaromatic-phenylthio group at the C-7 position exhibited significantly strong activities against S. pneumoniae and S. pyogenes with an erm gene even when compared with those of telithromycin. Finally, in vivo efficacy of selected two derivatives was evaluated in a rat pulmonary infection model with resistant S. pneumoniae with erm + mef genes. One of them exhibited strong and constant in vivo efficacy in this model, and both compounds showed strong in vivo efficacy against resistant S. pneumoniae with a mef gene.
为了对林可霉素 C-6 和 C-7 位进行修饰,我们应用钯催化交叉偶联反应作为关键反应,制备了在 6-氨基上具有取代的哌啶酸和在 C-7 位上具有对位取代的苯硫基的目标分子。在 6-位的构效关系(SAR)研究中,具有 4'-顺式-(环丙甲基)哌啶的类似物对具有 erm 基因的肺炎链球菌和化脓性链球菌表现出显著的强抗菌活性。基于 SAR,我们通过 C-7 取代基的转化进一步合成了具有 4'-顺式-(环丙甲基)哌啶的新型类似物。因此,具有对位杂芳基苯硫基的 C-7 位的新型衍生物对具有 erm 基因的肺炎链球菌和化脓性链球菌表现出显著的强活性,甚至与泰利霉素相比也是如此。最后,在携带 erm+mef 基因的耐药肺炎链球菌的大鼠肺部感染模型中评估了选定的两种衍生物的体内疗效。其中一种在该模型中表现出强而稳定的体内疗效,两种化合物对具有 mef 基因的耐药肺炎链球菌均表现出强的体内疗效。